Your browser doesn't support javascript.
loading
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
Pairawan, Seyed; Akcakanat, Argun; Kopetz, Scott; Tapia, Coya; Zheng, Xiaofeng; Chen, Huiqin; Ha, Min Jin; Rizvi, Yasmeen; Holla, Vijaykumar; Wang, Jing; Evans, Kurt W; Zhao, Ming; Busaidy, Naifa; Fang, Bingliang; Roth, Jack A; Dumbrava, Ecaterina Ileana; Meric-Bernstam, Funda.
Afiliação
  • Pairawan S; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Tapia C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Zheng X; Epizyme Inc., Boston, USA.
  • Chen H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Ha MJ; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Rizvi Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Holla V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Wang J; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Evans KW; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Zhao M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Busaidy N; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Fang B; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Dumbrava EI; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sci Rep ; 12(1): 1248, 2022 01 24.
Article em En | MEDLINE | ID: mdl-35075200
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Benzimidazóis / Neoplasias da Glândula Tireoide / Neoplasias Colorretais / Proteínas Proto-Oncogênicas c-mdm2 / Câncer Papilífero da Tireoide Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Benzimidazóis / Neoplasias da Glândula Tireoide / Neoplasias Colorretais / Proteínas Proto-Oncogênicas c-mdm2 / Câncer Papilífero da Tireoide Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos